FDA approves labeling changes warning of risks associated with psoriasis treatment
WASHINGTON The Food and Drug Administration has approved labeling changes, including a boxed warning, concerning the risk of possibly fatal infections from the psoriasis drug Raptiva, the agency announced Thursday.
The drug, marketed by Genentech and known generically as efalizumab, is a once-weekly injection for adults with moderate to severe plaque psoriasis.
The boxed warning will highlight the risk of bacterial sepsis, viral meningitis, invasive fungal disease, progressive multifocal leukoencephalopathy and other opportunistic infections.
Medicare patients not getting cancer screenings often enough
ROCKVILLE, Md. A study by researchers at the University of North Carolina shows that screening rates for certain types of cancer among older Medicaid patients lag behind national objectives.
The study, published in the Oct. 13 issue of the Archives of Internal Medicine and based on documented evidence, analyzed 1,951 Medicaid recipients in North Carolina aged 50 and older and found that physicians recommended screening for colorectal, breast and cervical cancer to 52.7 percent, 60.4 percent and 51.5 percent of patients, respectively.
Respective rates of adequate screening for the three cancers were 28.2 percent, 31.7 percent and 31.6 percent.
Report shows Philadelphia has high rate of those treated for diabetes type 2
PHILADELPHIA Percentages of people in Philadelphia who receive services to treat type 2 diabetes are higher than national averages. At the same time, the percentage of working-age people with the disease is higher in the city than the national average.
These are some of the results in the Greater Philadelphia Type 2 Diabetes Report for 2008, released Wednesday by the Greater Philadelphia Diabetes Coalition, which analyzed the demographics, costs and quality of care for people in the city with type 2 diabetes. The report included data from around the city’s metropolitan area, as well as western Pennsylvania and Atlantic City, N.J.
“GPDC helped develop the Greater Philadelphia Type 2 Diabetes Report to serve as a useful resource for employers, illustrating the seirous negative impact diabetes has on the Greater Philadelphia area,” GPDC chairman Dr. Ronald Brooks said. “This report points out the need to prevent diabetes through exercise and prudent nutrition as well as the importance that people with diabetes receive optimal care, based on evidence-based guidelines.”
The report also shows that 57 percent of Philadelphia residents in 2007 were between 18 and 64 years old, higher than the national average of 52.3 percent. In Atlantic City, the rate was 59.4 percent.
It also shows that costs for care of people with Type 2 diabetes are higher in Philadelphia than in the other five markets profiled. In 2007, the average hospital inpatient charges for treating Type 2 diabetics was $95,813, almost twice as high as the national average of $49,870. Hospital outpatient charges were $6,168, while the national average was $4,673.